Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
Emma Andersson, S. Pützer, Bhagwan Yadav, et al.
Leukemia (2017) Vol. 32, Iss. 3, pp. 774-787
Closed Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Machine learning and feature selection for drug response prediction in precision oncology applications
Mehreen Ali, Tero Aittokallio
Biophysical Reviews (2018) Vol. 11, Iss. 1, pp. 31-39
Open Access | Times Cited: 188
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2193-2227
Open Access | Times Cited: 107
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B. Staber, Marco Herling, Mar Bellido, et al.
Blood (2019) Vol. 134, Iss. 14, pp. 1132-1143
Open Access | Times Cited: 123
Drug-perturbation-based stratification of blood cancer
Sascha Dietrich, Małgorzata Oleś, Junyan Lu, et al.
Journal of Clinical Investigation (2017) Vol. 128, Iss. 1, pp. 427-445
Open Access | Times Cited: 113
Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics
Maria Koromina, Maria‐Theodora Pandi, George P. Patrinos
OMICS A Journal of Integrative Biology (2019) Vol. 23, Iss. 11, pp. 539-548
Open Access | Times Cited: 106
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining
Konstantinos Vougas, Theodore Sakellaropoulos, Athanassios Kotsinas, et al.
Pharmacology & Therapeutics (2019) Vol. 203, pp. 107395-107395
Open Access | Times Cited: 103
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 91
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
Daniel Thomalla, Laura Beckmann, Christina Grimm, et al.
Blood (2022) Vol. 140, Iss. 20, pp. 2113-2126
Open Access | Times Cited: 64
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
Liye He, Jing Tang, Emma Andersson, et al.
Cancer Research (2018) Vol. 78, Iss. 9, pp. 2407-2418
Open Access | Times Cited: 74
Structural and functional consequences of the STAT5BN642H driver mutation
Elvin D. de Araujo, Fettah Erdogan, Heidi A. Neubauer, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 67
Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
Elvin D. de Araujo, Anna Orlova, Heidi A. Neubauer, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1757-1757
Open Access | Times Cited: 60
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL
Linus Wahnschaffe, Till Braun, Sanna Timonen, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1833-1833
Open Access | Times Cited: 58
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Aleksandr Ianevski, Sanna Timonen, Alexander Kononov, et al.
PLoS Computational Biology (2020) Vol. 16, Iss. 2, pp. e1007604-e1007604
Open Access | Times Cited: 56
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity
Xiaoyang Li, Yuqi Jiang, Yuri K. Peterson, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 10, pp. 5501-5525
Open Access | Times Cited: 56
Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy
Anna A. Popova, Pavel A. Levkin
Advanced Therapeutics (2020) Vol. 3, Iss. 2
Open Access | Times Cited: 44
Advances and Perspectives in the Treatment of T-PLL
Till Braun, Jana von Jan, Linus Wahnschaffe, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 113-124
Open Access | Times Cited: 42
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
Krimo Toutah, Nabanita Nawar, Sanna Timonen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8486-8509
Open Access | Times Cited: 34
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma
Armando N. Bastidas Torres, Davy Cats, Jacoba J. Out‐Luiting, et al.
Haematologica (2021) Vol. 107, Iss. 3, pp. 702-714
Open Access | Times Cited: 33
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
Dipabarna Bhattacharya, Antonella Teramo, Vanessa Rebecca Gasparini, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 26
T-cell prolymphocytic leukemia, a case report and review of the literature
Luis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel Juárez‐Salcedo, Javier Loscertales, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2025) Vol. 33, Iss. 3, pp. 505-517
Closed Access
B and T cell prolymphocytic leukaemia
Matthew Cross, Claire Dearden
Best Practice & Research Clinical Haematology (2019) Vol. 32, Iss. 3, pp. 217-228
Closed Access | Times Cited: 42
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
Barbara Maurer, Harini Nivarthi, Bettina Wingelhofer, et al.
Haematologica (2019) Vol. 105, Iss. 2, pp. 435-447
Open Access | Times Cited: 40
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
Blood (2021) Vol. 137, Iss. 25, pp. 3495-3506
Open Access | Times Cited: 28
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Sophie Williams, Greg Wells, Samantha Conroy, et al.
Expert Reviews in Molecular Medicine (2022) Vol. 24
Open Access | Times Cited: 19
Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses
Jana von Jan, Sanna Timonen, Till Braun, et al.
Blood (2024) Vol. 144, Iss. 15, pp. 1595-1610
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top